Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Two key tailwinds appear to be lifting the stock today.
Source: fool.com
Page 4 - Intercept Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Intercept Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Intercept Pharmaceutical Today - Breaking & Trending Today
The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
/PRNewswire/ -- The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S....
Source: prnewswire.com
FDA Panel Votes Against Approval Of Intercept Pharma's Liver Disease Drug; Stock Down
A panel of advisers to the U.S. Food and Drug Administration voted against approving Intercept Pharmaceuticals' (ICPT) investigational treatment for Nonalcoholic steatohepatitis, a serious progressive liver disease.
Source: rttnews.com
Health News Roundup: CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology; WHO recommends new COVID shots should target only XBB variants and more
Governor Greg Gianforte, who has already authorized a bill to ban gender-affirming treatments for transgender minors this year, has until Sunday to sign or veto the new legislation, Senate Bill 458, or return it to the legislature for amendments. U.S. FDA approves Krystal Biotech's skin-disorder gene therapy The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading.
Source: devdiscourse.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept ...
NEW YORK, May 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT). Such investors are
Source: kentuckytoday.com